The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period

BMC Endocrine Disorders

Volumn 10, Issue , 2010, Pages

  Weeke, Peter ^a   Andersson, Charlotte ^a   Fosbøl, Emil L ^a   Brendorp, Bente ^a   Køber, Lars ^a   Sharma, Arya M ^b   Finer, Nick ^c   James, Philip T ^d   Caterson, Ian D ^e   Rode, Richard A ^f   Torp Pedersen, Christian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIBUTRAMINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFECT; EXERCISE; FEMALE; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SCREENING; SINGLE BLIND PROCEDURE; WEIGHT REDUCTION;

EID: 77949384561     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-10-3     Document Type: Article

References (24)

1. Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008, 31:1582-1584. 10.2337/dc08-0025, 2494632, 18458146.
2. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898-918. 10.1161/CIRCULATIONAHA.106.171016, 16380542.
3. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007, 298:2028-2037. 10.1001/jama.298.17.2028, 17986696.
4. Haslam DW, James WP. Obesity. Lancet 2005, 366:1197-1209. 10.1016/S0140-6736(05)67483-1, 16198769.
5. Mauro M, Taylor V, Wharton S, Sharma AM. Barriers to obesity treatment. Eur J Intern Med 2008, 19:173-180. 10.1016/j.ejim.2007.09.011, 18395160.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
7. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007, 28:2915-2923. 10.1093/eurheartj/ehm217, 17595194.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
9. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007, 28:2375-2414. 10.1093/eurheartj/ehm316, 17726041.
10. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006, 98:1363-1368. 10.1016/j.amjcard.2006.06.032, 17134630.
11. Wilson PW, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008, 118:124-130. 10.1161/CIRCULATIONAHA.108.772962, 18591432.
12. Halle M, Berg A, Frey I, Konig D, Keul J, Baumstark MW. Relationship between obesity and concentration and composition of low-density lipoprotein subfractions in normoinsulinemic men. Metabolism 1995, 44:1384-1390. 10.1016/0026-0495(95)90134-5, 7476322.
13. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601-1610. 10.1016/S0195-668X(03)00347-6, 12964575.
14. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046-3051. 10.1161/hc5001.100624, 11748098.
15. Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, van Dam RM, Hu FB, Visscher TL, Menotti A, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007, 167:1720-1728. 10.1001/archinte.167.16.1720, 17846390.
16. Brunner EJ, Thorogood M, Rees K, Hewitt G. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2005, CD002128.
17. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006, 8:206-213. 10.1111/j.1463-1326.2005.00481.x, 16448525.
18. DeFaria Yeh D, Freeman MW, Meigs JB, Grant RW. Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterol. Am J Cardiol 2007, 99:1-4. 10.1016/j.amjcard.2006.07.053, 17196452.
19. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029-1036.
20. Schieffer B, Moore D, Funke E, Hogan S, Alphin F, Hamilton M, Heyden S. Reduction of atherogenic risk factors by short-term weight reduction. Evidence of the efficacy of National Cholesterol Education Program guidelines for the obese. Klin Wochenschr 1991, 69:163-167. 10.1007/BF01665860, 2041377.
21. Shechter M, Beigel R, Freimark D, Matetzky S, Feinberg MS. Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. Am J Cardiol 2006, 97:1650-1653. 10.1016/j.amjcard.2005.12.059, 16728231.
22. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001, 142:489-497. 10.1067/mhj.2001.117510, 11526363.
23. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356:2119-2125. 10.1016/S0140-6736(00)03491-7, 11191537.
24. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007, 176:1113-1120. 1839776, 17420495.